Søren Hough
@sorenhough.bsky.social
Cancer biologist/science+film journalist. Freelance at RogerEbert.com. Editor at The Commoner. EIC at Movie Fail. PhD (Biochemistry). Editing w/ pen + #CRISPR 🍞🏴 https://sorenhough.com/
Instead of walking away after the EMA's decision, Roche is running another Phase III study to generate the additional efficacy and safety data needed for Europe. For families waiting on treatment, that's worth watching! www.bioxconomy.com/modalities/s...
Roche launches additional Phase III DMD trial to win over EMA
The European regulator denied the company marketing authorization last year after Elevidys failed to meet endpoints.
bioxconomy.com
Had the good fortune to bring my science and film journalism together for this one! I wrote about how Spider-Man: Brand New Day tackles some serious scientific ideas and their ethical implications, and mostly succeeds: www.bioxconomy.com/modalities/r...
RNA and ethical quandaries in Spider-Man: Brand New Day
Marvel’s latest web-crawling adventure features a surprising dive into cutting-edge medicine, providing an opportunity for effective science communication.
bioxconomy.com
Another tale of Lucky Jack Pawbrey and his particular friend Stephen Caturin
The Sacramento Bee@sacbee.com · 2w agoThe Tacoma Police Department estimates over 30 cats were free-roaming on board a deserted watercraft Thursday - with no sign of the owner.
Clairement mais cela s'internationalise vite quand même. J'aimerais tellement qu'il existe une photo de James Guillaume (suisse né à Londres et naturalisé français) et Marie Goldsmith (russe vivant en France) au défilé du 1er mai place de la République à Paris en 1906 jguillaume.hypotheses.org/1516
James Guillaume et Marie Goldsmith (1904-1916)
Photographie de Marie Goldsmith (1873-1933) conservée aux AEN. Elle accompagnait une de ses lettres du 19 octobre 1916 cotée 55.21 avec la mention manuscrite suivante : “À notre ami James Guillaume. S...
jguillaume.hypotheses.org
New chapter by Søren Hough on Russian scientist and anarchist Marie Goldsmith out now: "Anarchism through Biology: Marie Goldsmith’s Liberatory Science in Practice" brill.com/display/book...
brill.com
RFK Jr & his closest MAHA ally Jay Bhattacharya are going to be sad & angry When they canceled federal funding for mRNA vaccine R&D, they each wrote utterly pathetic editorials defending their decision (I was interviewed about those ridiculous OpEds here: www.bioxconomy.com/modalities/e...)
—RFK Jr ended federal support for mRNA vaccine R&D; then, of course, Jay Bhattacharya wrote an unsubstantiated opinion piece praising RFK Jr’s action (I called Jay’s piece “anti-scientific” in this news article by @sorenhough.bsky.social) 11/n www.bioxconomy.com/modalities/e...
Experts reject HHS disparagement of mRNA technology
World-leading vaccine and public health experts say NIH director Jay Bhattacharya’s recent op-ed is “infuriating” and “anti-scientific.”
bioxconomy.com
Experimental DIY peptides are taking the US by storm. BioXconomy and BPI investigate the booming underground peptide market - and the dangers it brings with it. Read my full investigative piece below: #peptide #glp #investigation www.bioxconomy.com/modalities/d...
Experimental injectable peptides craze takes US by storm
BioXconomy and BPI investigate the booming underground peptide market – and the dangers it brings with it.
bioxconomy.com
Capsida confirms the closure of the SYNRGY trial, with the safety of its gene therapy remaining unknown. The clinical trial for the rare disease STXBP1 was originally put on hold following the death of a child. Read my full article here: #clinicaltrial #capsida www.bioxconomy.com/modalities/c...
Capsida confirms closure of SYNRGY gene therapy trial
The clinical trial for the rare disease STXBP1 was originally put on hold following the death of a child.
bioxconomy.com
Antibody developers are seeing regulatory wins and clinical trial successes for several different forms of cancer. From trial successes and approvals, antibodies are achieving better results than thought possible. Read my full article here: #antibodies #cancer www.bioxconomy.com/modalities/a...
Antibody earthquake immunotherapies reach cancer patients
Antibody drug developers are seeing regulatory wins and clinical trial successes for several different forms of cancer.
bioxconomy.com
UK’s NICE approves reimbursement of Genmab’s cervical cancer antibody drug. The regulatory body changed its opinion on antibody conjugate therapy Tivdak, paving the way for NHS use. Full article below: #NICE #cervicalcancer www.bioxconomy.com/modalities/u...
UK's NICE approves reimbursement of cervical cancer antibody drug
The regulatory body changed its opinion on antibody conjugate therapy Tivdak, paving way for NHS use.
bioxconomy.com
Normal phenylalanine levels in 48 hrs via base editing mRNA? That's just... amazing. A potentially permanent solution for PKU!
'Baby KJ' CRISPR treatment was just the beginning
Scientists have successfully used a base editing mRNA-LNP approach to correct genetic variants responsible for phenylketonuria (PKU), a severe metabolic condition. This non-viral gene editing method d
bioxconomy.com
The University of Barcelona is building a not-for-profit manufacturing model to get CAR Ts to patients sooner. Read my full article below: #nonprofit #CART #barcelona www.bioprocessintl.com/therapeutic-...
University of Barcelona tackles CAR-T therapy accessibility
University of Barcelona develops ARI-0001, a not-for-profit CAR-T therapy using EU hospital exemption rules to improve patient access to cancer treatment.
bioprocessintl.com
Precious few people in the world have been able to bring hope to folks with nano-rare conditions. Stan Crooke is one of those people. So you can imagine how excited AJ and I were to chat with Stan on the latest episode of Dose of Discovery (see thread below).
So honored to share our first peer-reviewed chapter on Marie Goldsmith, now out from Brill. Chris and I dive into the three pillars that shaped Goldsmith's outlook: positivist-influenced philosophy, radical politics, and scientific evidentialism.
Ole Birk Laursen@olebirklaursen.bsky.social · 3mo agoNew chapter by Søren Hough on Russian scientist and anarchist Marie Goldsmith out now: "Anarchism through Biology: Marie Goldsmith’s Liberatory Science in Practice" brill.com/display/book...
Pharma giant GSK says it has seen positive results from its BEHOLD-1 trial treating ovarian and endometrial cancer. Read my full article below: #gsk #oncology www.bioxconomy.com/modalities/g...
GSK’s ADC succeeds in treating advanced gynecological cancers
The pharma giant says it has seen positive results from its BEHOLD-1 trial treating ovarian and endometrial cancer.
bioxconomy.com
Boehringer Ingelheim are set to partner with OpenProtein.AI The collaboration will focus on the co-development of an AI antibody discovery platform. Read my full article below: #AI #antibody www.bioxconomy.com/modalities/p...
Boehringer Ingelheim partners with OpenProtein.AI
The collaboration will focus on the co-development of an AI antibody discovery platform.
bioxconomy.com
New clinical trial results show promise for a monoclonal antibody immunosuppressant, allowing pancreatic islet transplants in diabetes patients. Read my full article below: #diabetes #transplant #antibodies www.bioxconomy.com/modalities/m...
mAb-based immunosuppressant supports diabetes cell transplants
New clinical trial results show promise for a monoclonal antibody immunosuppressant.
bioxconomy.com
Lipid nanoparticles have transformed the way biologics are delivered, creating robust and highly specific treatment options across a range of conditions. Read my roundup on LNPs below: #LNPs #mRNA www.bioxconomy.com/modalities/l...
LNP versatility: From scarless healing to pancreatic cancer
Lipid nanoparticles have transformed the way biologics are delivered, creating robust and highly specific treatment options across a range of conditions.
bioxconomy.com
This is such an impressive investigative piece from @milliehoe.bsky.social. It was an honor to get the chance to edit it alongside Josh Abbott. If you haven't given it a read, set aside a few minutes and check it out! Promise it's worth it.
Millie Hoe Science Journalist@milliehoe.bsky.social · 3mo agoExperimental DIY peptides are taking the US by storm. BioXconomy and BPI investigate the booming underground peptide market - and the dangers it brings with it. Read my full investigative piece below: #peptide #glp #investigation www.bioxconomy.com/modalities/d...
This has been a long time coming, and I couldn't be more excited to share the news: our new science interview podcast, Dose of Discovery, is live!
Bhattacharya killing one of the most promising technologies in a generation for improving health, treating disease, & preventing mass death from pandemics was unforgivable; this will be his legacy I was interviewed about his lies about mRNA vaccines here: www.bioxconomy.com/modalities/e...
Experts reject HHS disparagement of mRNA technology
World-leading vaccine and public health experts say NIH director Jay Bhattacharya’s recent op-ed is “infuriating” and “anti-scientific.”
bioxconomy.com
Jonathan Howard@joho.bsky.social · 4mo agoJay Bhattacharya: Why the NIH is pivoting away from mRNA vaccines "As a vaccine for broad public use, mRNA technology has failed to earn the public’s trust."
Monoclonal antibody cocktails show promise in combating RSV, reducing viral titers in studies. A new frontier in respiratory infection prevention. #RSV #AntibodyTherapy Read my full article below: www.bioxconomy.com/modalities/s...
Using monoclonal antibody cocktails to fight RSV
Researchers at two Chinese universities have shown that combination antibody therapies could prevent respiratory infections.
bioxconomy.com
Peptides market to explode following success of GLP-1s. Experts predict a value of almost $300 billion by 2033, with the US dominating more than 60% of the market. #news #invest #glps Read my full article below: www.bioxconomy.com/modalities/p...
Peptide therapeutics market set to soar
The US is driving innovation in the peptide therapeutics space, especially around GLP-1s.
bioxconomy.com
‘Quieting craving itself’: GLP-1s reduce risk of substance addiction in US veterans In a landmark observational study of over 600,000 US veterans with type-2 diabetes, #GLPs reduced addiction rates and adverse outcomes. Read my full article below: #news #science www.bioxconomy.com/modalities/q...
GLP-1s reduce risk of substance addiction in US veterans
A study of over 600,000 veterans suggests GLP-1s reduce the chances of developing addiction while improving outcomes for those already addicted.
bioxconomy.com
CDMO Neuland Laboratories announced that it will open its peptide facility in summer 2026. The site, which will produce glucagon-like peptide-1 (GLP-1s), is just 40 miles from Hyderabad, India. Read my full article below: #peptide #GLP www.bioxconomy.com/modalities/n...
Neuland announces plans for Hyderabad GLP-1 CMC facility
Located in the village of Bonthapally, the peptide CMC site is set to open summer 2026.
bioxconomy.com
Researchers from Columbia University were able to up-regulate a cardio-protective peptide in animal models using self-amplifying RNA. The peptide preserves cardiac function after a heart attack. Read my full article below: #heart #peptide #heartattack www.bioxconomy.com/modalities/h...
RNA-delivered peptide boosts recovery after heart attack
A self-amplifying RNA with a “smart drug activation system” provides heart tissue-specific regeneration.
bioxconomy.com
The FDA asked pharma company UniQure for a “double-blind, sham surgery-controlled study” of its mutation-rescuing Huntington’s disease therapy. Study leader Edward Wild has expressed ethical concerns. Read my full article below: #FDA #Huntington #genetherapy www.bioxconomy.com/modalities/f...
FDA demands sham arm for Huntington’s gene therapy
The US agency’s U-turn would postpone treatment for participants in the placebo group.
bioxconomy.com
What happens to gene therapies that are proven to save lives, but that are not commercially viable? Academic institutions are picking up the slack in a for-profit industry. Read my full article below: #genetherapy #access #nonprofit www.bioprocessintl.com/upstream-dow...
Academic institutions tackle gene therapy costs and accessibility
Academics innovate gene therapy manufacturing to cut costs and improve access, addressing commercialization challenges and saving lives worldwide
bioprocessintl.com
